Trial | Synonym | Years trial | N total | med. Age | FU (y) | Post meno- pausal | HR+ | CTx | N+ | N- | T1 | T2 | Lateral Location | Surgery | Dose Breast | Dose RN | RT Boost | IMN TV | Main trial group |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hennequin 2013 | French | 1991–1997 | 1407 | n.r. | 8.6 | n.r. | 52% | 61% | 75% | 25% | 33% | 52% | 36% | MTx 100 AND 100% | 50Gy | 18 × 2.5 Gy =45Gy | none | ICS 1–5 | N0 med/ central or N+ |
Thorsen 2016 | DBCG- IMN | 2003–2007 | 3377 | 56 | 8.9 | 60% | 80% | 53% | 100% | 0% | 41% | 52% | 60% | BCS 35% MTx 65 AND 100% | 24x2Gy =48Gy | 24x2Gy =48Gy | 13% | ICS 1–4 | N+ |
Poortmans 2015/2018 | EORTC 22922 | 1996–2004 | 4004 | 54 | 15.7 | 59% | 78% | 55% | 56% | 45% | 60% | 36% | n.r. | BCS 76,1% MTx 23,9% AND 100% | 25x2Gy =50Gy | 25x2Gy =50Gy | 85% | ICS 1–3 (−4) | N0 med/ central or N+ |
Whelan 2015 | Ma.20 | 2000–2007 | 1832 | 54 | 9.5 | nr | 75% | 91% | 90% | 10% | 52% | 46% | 62% | BCS 100 AND 96% SNB 4% | 25x2Gy =50Gy | 25 × 1.8–2 Gy =45-50Gy | 33% | ICS 1–3 | N0 (high risk) or N+ |